63284-72-0

Basic information

• Product Name: Citalopram N-Oxide
• Synonyms: 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile N1-Oxide;1-[3-(Dimethyloxidoamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro -5-isobenzofurancarbonitrile;Citalopram N-Oxide;Lu 11-305;1-(4-Fluorophenyl)-1-[3-(dimethyl oxide amino)propyl]-1,3-dihydroisobenzofuran-5-carbonitrile;Dimethyl[3-[1-(4-fluorophenyl)-5-cyano-1,3-dihydroisobenzofuran-1-yl]propyl]amine N-oxide;N,N-Dimethyl-3-[[1-(4-fluorophenyl)-5-cyano-1,3-dihydroisobenzofuran]-1-yl]-1-propanamine N-oxide;CitalopraM USP Related CoMpound E
• CAS NO: 63284-72-0
• Molecular Formula: C₂₀H₂₁FN₂O₂
• Molecular Weight: 340.3913432
• Product Categories: Heterocyclic Compounds;Heterocycles;Metabolites & Impurities
• Mol File: 63284-72-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 91-93°C
• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.73±0.40(Predicted)
• CAS DataBase Reference: Citalopram N-Oxide(CAS DataBase Reference)
• NIST Chemistry Reference: Citalopram N-Oxide(63284-72-0)
• EPA Substance Registry System: Citalopram N-Oxide(63284-72-0)

Safety Data

• Hazardous Substances Data: 63284-72-0(Hazardous Substances Data)

Usage

Description

Citalopram N-Oxide, also known as Escitalopram EP Impurity H and Citalopram USP Related Compound E, is a metabolite of Citalopram (CT). It is a white solid with specific chemical properties that make it significant in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
Citalopram N-Oxide is used as a metabolite for [application reason]. As a metabolite of Citalopram, it plays a role in the study and understanding of the drug's pharmacokinetics, pharmacodynamics, and potential effects on the human body. This information can be crucial for the development of new drugs, drug interactions, and the optimization of dosages.

InChI:InChI=1/C20H21FN2O2/c1-23(2,24)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-25-20/h4-9,12H,3,10-11,14H2,1-2H3

Upstream product

• 59729-32-7 citalopram hydrobromide 
• 59729-33-8 1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile 

Relevant articles and documents

Effect of CYP2D6 genetic polymorphism on the metabolism of citalopram in vitro

Genetic polymorphisms of CYP2D6 significantly influence the efficacy and safety of some drugs, which might cause adverse effects and therapeutic failure. We aimed at investigating the role of CYP2D6 in the metabolism of citalopram and identifying the effect of 24 CYP2D6 allelic variants we found in Chinese Han population on the metabolism of citalopram in vitro. These CYP2D6 variants expressed by insect cells system were incubated with 10-1000 μM citalopram for 30 min at 37 °C and the reaction was terminated by cooling to -80 °C immediately. Citalopram and its metabolites were analyzed by high-performance liquid chromatography (HPLC). The intrinsic clearance (Vmax/Km) values of the variants toward citalopram metabolites were significantly altered, 38-129% for demethylcitalopram and 13-138% for citalopram N-oxide when compared with CYP2D6?1. Most of the tested rare alleles exhibited significantly decreased values due to increased Km and/or decreased Vmax values. We conclude that recombinant system could be used to investigate the enzymes involved in drug metabolism and these findings suggest that more attention should be paid to subjects carrying these CYP2D6 alleles when administering citalopram in the clinic.